SCHEDULE: Redmile Group Maintains 8.5% Stake in ALX Oncology

Redmile Group, LLC and its affiliates disclosed continued significant beneficial ownership of 8.5% in ALX Oncology Holdings Inc. common stock.

Summary

• Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in ALX Oncology Holdings Inc.
• Redmile Group, LLC and Jeremy C. Green each beneficially own 4,641,455 shares of ALX Oncology Holdings Inc. common stock, representing 8.5% of the class.
• This ownership includes 3,391,455 common shares and 1,250,000 shares issuable upon exercise of warrants.
• Redmile Biopharma Investments III, L.P. beneficially owns 3,675,481 shares, equating to 6.7% of the class, comprising 2,425,481 common shares and 1,250,000 shares from warrants directly held by RBI III.
• The percentages are calculated based on 53,444,020 shares of common stock outstanding as of May 1, 2025, plus the 1,250,000 shares issuable from warrants.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The filing is neutral in its direct content as it's a factual ownership disclosure. However, the continued significant stake by a specialized investment group like Redmile Group can be interpreted as a positive signal of investor confidence in ALX Oncology Holdings Inc.

Positives

• A significant institutional investor, Redmile Group, LLC, maintains a substantial 8.5% stake, indicating continued confidence in ALX Oncology Holdings Inc.

Negatives

• NA

Risks

• The value of the investment is subject to market fluctuations inherent in holding common stock and warrants.
• The beneficial ownership includes shares issuable upon exercise of warrants, which could lead to dilution if exercised.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.

Industry Context

This filing reflects a significant investment by a specialized biopharma investment firm in a biotechnology company, which is common practice for institutional investors seeking exposure to the life sciences sector. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's continued stake in the company, which may influence investor sentiment and perception of stability.

Key Dates

Keywords

ALX Oncology Holdings Inc., Redmile Group, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biopharma Investments